Phase 2 N=3 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: PFS
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=116 Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
Safety and Tolerability · Compare SHINGRIX Vaccine Response Rates · Chronic Lymphocytic Leukemia (CLL)
Primary: Number of Participants With Varicella Zoster Virus (VZV) Seroprotective Titer — 43; 11; 9 Participants
Phase 2 N=30 Topical Capsaicin for Cyclical Vomiting
Cyclical Vomiting
Primary: Nausea Visual Analog Scale — 41; 61 mm
Phase 2 N=78 HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
Hepatitis · Safety and Tolerability
Primary: Number of Participants With HEPLISAV-B Seroprotective Titer (Anti-HBs 10mIU/mL) — 0; 1; 9 Participants
Phase 2 N=60 Atovaquone for Treatment of COVID-19
COVID-19
Primary: Primary Analysis — -1.906; 2.629; 4.073 log 10 (copies/mL) — p=0.170
Phase 2 N=23 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Neuroendocrine Tumors · Carcinoma, Small Cell Lung · Neuroendocrine Carcinoma
Primary: Phase 1: Maximum Tolerated Dose of PEN-221 and Recommended Phase 2a Dose (RP2D) — 18.0 mg
Phase 2 N=104 Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
ALK-positive Advanced NSCLC
Primary: Confirmed Objective Response Rate (ORR) in the Main Cohort of the Refractory Expansion Part — 34.0 percentage of participants
Phase 2 N=120 A Study of Acute Myocardial Infarction Using FDY-5301
Acute Myocardial Infarction · STEMI
Primary: Arrhythmias of Interest, 48 Hours (Overall) — 0; 0; 0; 0 participants
Phase 2 N=165 Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)
Dry Eye Disease
Primary: Schirmer's Test Score at Day 1 — 9.0; 17.5; 19.6; 3.0 mm
Phase 2 N=610 An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects
Asthma
Primary: Pre-dose Morning FEV1 at Week 8 - Change From Baseline — 0.021; 0.090; 0.070; -0.023 Litres — p=0.567
Phase 2 N=70 Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Colorectal Cancer
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator — 7.1 percentage (%) of participants — p=0.2721
Phase 2 N=82 Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B
Chronic Hepatitis B
Primary: Incidence of Adverse Events (AEs) — 4; 3; 4; 5 Participants
Phase 2 N=419 Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants
Respiratory Syncytial Virus Infections
Primary: Percentage of Maternal Subjects With Any Solicited Administration Site Events — 57.1; 52; 15.2; 1.4 Percentage of maternal subjects
Phase 2 N=140 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
Toxic Shock Syndrome
Primary: Number of Participants (Percentage) With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment — 9; 11; 11; 12 Participants
Phase 2 N=157 A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
Vitiligo
Primary: Percentage of Participants Treated With Ruxolitinib Cream Who Achieved a ≥ 50% Improvement From Baseline in Facial Assessment of the Vitiligo Area and Severity Index…